Letter Regarding “Overcoming Clinical Inertia in the Context of Non-Adherence With Guideline-Directed Medical Therapy for Heart Failure”

The publication by Okumura and associates reviewed the impact of 2 factors, clinical inertia and non-adherence, on the provision of guideline-directed medical therapy (GDMT) for patients with heart failure (HF),1 which we found to be of particular interest. This article was published at a time when there were still many examples of a disconnect between evidence-based practice and what was happening in real practice. This disconnect affects the survival rates and quality of life for people living with HF globally.2 We agree with the central message of the article that delayed initiation, suboptimal titration, and inadequate reassessment of GDMT substantially contribute to the persistent evidence-to-practice gap in HF care, and that the speed of implementation is a determinant of outcomes rather than a secondary consideration. Three targeted extensions are proposed to enhance the translational applicability of the article to global cardiology practice and to provide practical considerations for healthcare systems across different countries, where medical systems may vary considerably. Clinical inertia is often discussed as a limitation of clinical practitioners; however, it is important to note that there are many reasons not to increase the intensity of treatment, including but not limited to rational clinical decision-making, transient clinical conditions, fragmented follow-up care, or system-level constraints.3 First, in this context, we suggest that clinical inertia should not be viewed solely as a physician’s reluctance, but rather as a spectrum that includes avoidable inertia and constrained-care inertia driven by system limitations. Second, to better understand and replicate the concept of clinical inertia, we suggest that it should be measured and defined by the use of objective, audited indicators within the care pathway for cardiology patients: time-to-initiation of foundational GDMT classes, time-to-dose optimisation toward evidence-based thresholds, and time-to-reassessment following sentinel events (hospital discharge, renal function changes, hypotension, and electrolyte disturbances). Metrics such as these allow for comparisons of institutional and geographical differences in system performance related to inertia, with this measure now being viewed as something that can be improved or modified. In addition to promoting uniform adoption of GDMTs, current clinical data suggest that system performance speed and system structure are paramount to initial patient therapy delivery. Prior expert synthesis has shown that the implementation of early optimized foundational HF therapy and rapid sequencing is possible and has clinical significance when combined with protocol-based workflows and a team of multi-disciplinary services.4 Additional randomized studies have also supported this approach. In the Safety, Tolerability and Efficacy of Rapid Optimization of Heart Failure Therapies (STRONG-HF) trial, patients who received structured early follow-up, in addition to rapid dosage increase and close monitoring after acute HF, experienced lower rates of adverse outcomes compared with patients receiving usual care.5 Furthermore, this represents an implementation model, not just pharmacotherapy recommendations. Subsequent evidence has identified pragmatic principles to identify “time to quadruple therapy” as a modifiable influence on outcomes, rather than simply an aspiration or end-goal.6 Based on these findings, we recommend that standardized rapid-sequence GDMT bundles—including initiation on the day of discharge, predefined laboratory checkpoints, and delegated authority for titration—be incorporated into HF quality-improvement initiatives. Third, for low- and middle-income countries and other settings with limited resources, the under-use of GDMT may be more related to access and economic constraints, rather than to the physician’s reluctance to prescribe GDMT and/or patient non-adherence. Reviewing essential medicines lists and pricing data across international markets shows that many cornerstone HF therapies remain inconsistently available or are priced beyond the reach of a large proportion of patients. This has created an environment in which “non-adherence” becomes a structural inevitability.7 Previous affordability research has highlighted concerns regarding medications that, while commercially available, do not allow optimal dosing regimens to reach many patients.8 Recognizing constrained-care inertia as distinct from avoidable clinical inertia may help redirect solutions toward policy-level interventions such as formulary prioritisation, pooled procurement, and context-specific sequencing strategies. While there has been a significant increase in the use of technology for digital decision-making, telehealth monitoring, and other methods to enhance the timeliness of GDMT titration, their impact can only be realized through equitable access and intentional implementation. Digital optimization strategies must therefore address sociotechnical barriers. Otherwise, they risk exacerbating healthcare disparities or creating new forms of workflow-related inertia.9,10 Based on the findings of Okumura et al1, clinical inertia in HF should be operationalised through the implementation of rapid sequencing and early surveillance systems, together with explicit evaluation of equity constraints. By transforming clinical inertia into a measurable, actionable, and adaptable process, the focus shifts from attribution of blame to the design of scalable improvement pipelines across diverse health systems. Acknowledgements The authors thank colleagues in the Department of Medical Laboratory Technology, University Institute of Allied Health Sciences, Chandigarh University, for informal academic discussions that contributed to conceptual clarity. Funding None. Author contributions M. Vijayasimha: Conceptualization, critical analysis, manuscript drafting, and final approval of the version to be submitted. M. Srikanth: Literature review, intellectual input, manuscript revision for important clinical and scientific content, and final approval of the version to be submitted. Chinmaya Mahapatra: Data interpretation, literature support, manuscript editing, and final approval of the version to be submitted. All authors contributed to the article and approved the submitted version and agree to be accountable for all aspects of the work. Conflicts of interest None.